SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
STRYKER CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$297.94+3.28 (+1.11%)
Close on Oct 19, 2026
- Market cap
- $115.00B
- P/E (TTM)
- 30.9
- Dividend yield
- –
STRYKER CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $15.65B | $13.52B | $12.16B | $10.89B | $9.54B | $8.35B | $8.48B | – | – | – | 62.3% | +15.7% |
| Orthopaedics: | $9.47B | $9.08B | $8.34B | $7.56B | $7.57B | $6.01B | $6.41B | – | – | – | 37.7% | +4.3% |
| Orthopaedics | $9.47B | $9.08B | $8.34B | $7.56B | – | $4.96B | $5.25B | $4.99B | $4.71B | $4.42B | 37.7% | +4.3% |
| Orthopaedics | – | – | – | – | – | $4.96B | $5.25B | $4.99B | $4.71B | $4.42B | – | – |
| Neurotechnology and Spine | – | – | – | – | – | $2.99B | $3.14B | $2.57B | $2.17B | $2.01B | – | – |
| MedSurg | – | – | – | – | – | $6.40B | $6.49B | $6.05B | $5.56B | $4.89B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $4.67B | $4.00B | $3.47B | $2.83B | $2.81B | $2.41B | $2.30B | – | – | – | +16.7% |
| Orthopaedics | $2.82B | $2.59B | $2.27B | $2.20B | – | – | – | – | – | – | +8.8% |
| Orthopaedics: | – | – | $2.40B | $2.30B | $2.18B | $1.59B | $2.08B | – | – | – | – |
| Orthopaedics | – | – | – | – | – | $1.52B | $1.91B | $1.80B | $1.68B | $1.60B | – |
| Neurotechnology and Spine | – | – | – | – | – | $647.00M | $839.00M | $700.00M | $631.00M | $559.00M | – |
| MedSurg | – | – | – | – | – | $1.84B | $1.64B | $1.44B | $1.23B | $1.09B | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other MedSurg And Neurotechnology | – | – | $343.00M | $302.00M | $277.00M | – | – | – | – | – | – | – |
| Neuro Cranial - Interventional Spine | – | $413.00M | $327.00M | $282.00M | – | – | – | – | – | – | – | – |
| Other Orthopedics - Enabling Technologies | – | $152.00M | $149.00M | $131.00M | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $19.01B | $16.94B | $15.26B | $13.64B | $12.32B | $10.46B | $10.96B | $9.85B | $9.06B | $8.23B | 75.7% | +12.2% |
| International | $6.11B | $5.65B | $5.24B | $4.81B | $4.79B | $3.90B | $3.93B | $3.75B | $3.39B | $3.10B | 24.3% | +8.1% |
| Europe, Middle East, Africa | $3.18B | $2.90B | $2.62B | $2.35B | $2.30B | $1.82B | $1.89B | $1.79B | $1.57B | $1.44B | 12.7% | +9.8% |
| Asia Pacific | $2.16B | $2.02B | $1.95B | $1.89B | $1.97B | $1.63B | $1.62B | $1.53B | $1.41B | $1.33B | 8.6% | +7.1% |
| Other foreign countries | $765.00M | $735.00M | $677.00M | $578.00M | $515.00M | $448.00M | $422.00M | $428.00M | $405.00M | $333.00M | 3.0% | +4.1% |
From the segment and revenue-disaggregation notes of Stryker's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.